{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:00:55Z","timestamp":1792098055169,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T00:00:00Z","timestamp":1301443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the efficacy and safety of adalimumab versus infliximab in an open\u2010label prospective, comparative, multicenter cohort study of childhood noninfectious chronic uveitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Thirty\u2010three patients (22 females, 11 males, median age 9.17 years) with refractory, vision\u2010threatening, noninfectious active uveitis were enrolled, and received for at least 1 year infliximab (5 mg\/kg at weeks 0, 2, and 6, and then every 6\u20138 weeks) or adalimumab (24 mg\/m<jats:sup>2<\/jats:sup> every 2 weeks). The primary outcome was to assess, once remission was achieved, the time of a first relapse. Time to remission, time to steroid discontinuation, and the number of relapses were also considered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixteen children (12 with juvenile idiopathic arthritis [JIA], 3 with idiopathic uveitis, and 1 with Beh\u00e7et's disease) were recruited in the adalimumab cohort and 17 children (10 with JIA, 5 with idiopathic uveitis, 1 with early\u2010onset sarcoidosis, and 1 with Beh\u00e7et's disease) were recruited in the infliximab group. Cox regression analysis did not show statistically significant differences between the two groups with regard to time to achieve remission and time to steroid discontinuation, whereas a higher probability of uveitis remission on adalimumab during the time of treatment was shown (Mantel\u2010Cox \u03c7<jats:sup>2<\/jats:sup> = 6.83, <jats:italic>P<\/jats:italic> &lt; 0.001). At 40 months of followup, 9 (60%) of 15 children receiving adalimumab compared to 3 (18.8%) of 16 children receiving infliximab were still in remission on therapy (<jats:italic>P<\/jats:italic> &lt; 0.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Even if limited to a relatively small group, our study suggests that over 3 years of treatment, adalimumab is more efficacious than infliximab in maintaining remission of chronic childhood uveitis.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.20404","type":"journal-article","created":{"date-parts":[[2010,11,15]],"date-time":"2010-11-15T12:04:38Z","timestamp":1289822678000},"page":"612-618","source":"Crossref","is-referenced-by-count":169,"title":["Prevention of flare recurrences in childhood\u2010refractory chronic uveitis: An open\u2010label comparative study of adalimumab versus infliximab"],"prefix":"10.1002","volume":"63","author":[{"given":"Gabriele","family":"Simonini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Taddio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cattalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"De Libero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Naviglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Bresci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Lepore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolando","family":"Cimaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,30]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.8.4.251.6459"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728220902852570"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel030"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0b013e31817d7107"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.01.005"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2005.01062.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.7.903"},{"key":"e_1_2_6_9_2","first-page":"1146","article-title":"Tumor necrosis factor\u2010\u03b1 blocker in treatment of juvenile idiopathic arthritis\u2013associated uveitis refractory to second line agents: results of a multinational survey","volume":"34","author":"Foeldvari I","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.04.058"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.103721"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.108050"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken298"},{"key":"e_1_2_6_14_2","first-page":"S95","article-title":"Comparison between infliximab and adalimumab for the treatment of refractory chronic uveitis in childhood","volume":"60","author":"Simonini G","year":"2009","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.12.009"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.3758\/BF03203630"},{"key":"e_1_2_6_18_2","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen J","year":"1988"},{"key":"e_1_2_6_19_2","first-page":"1","article-title":"New treatment approaches in juvenile idiopathic arthritis","volume":"7","author":"Holzinger D","year":"2009","journal-title":"Int J Adv Rheumatol"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e3283126d20"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2005.01062.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.124081"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058248"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2008.08.007"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.09.037"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.08.018"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.141"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem356"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2009.203"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.20404","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.20404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:38:44Z","timestamp":1759415924000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.20404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,30]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1002\/acr.20404"],"URL":"https:\/\/doi.org\/10.1002\/acr.20404","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,30]]}}}